RecruitMe Clinical Trial

A PHASE II OPEN LABEL, RANDOMIZED NON-COMPARATIVE TRIAL OF NIVOLUMAB ALONE OR IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED HYPERMUTATED SOLID TUMORS DETECTED BY A BLOOD BASED ASSAY- Nivolumab Ipilimumab in Patients with HyperMutated Cancers Detected in BLood (NIMBLe)
Study of Nivolumab Alone or in Combination with Ipilimumab for the Treatment of Patients with Advanced Hypermutated Solid Tumors
Sponsor:Canadian Cancer Trials Group
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9508
U.S. Government ID:NCT03461952
Contact: Naiyer Rizvi, MD: 646-317-3141 / nar2144@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find out what effects nivolumab or nivolumab given in combination with ipilimumab have on you and your cancer given the presence of genetic biomarkers (POLE and POLD1). This study will also look at the side effects of these two new immunotherapy drugs.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have an advanced solid tumor?YesNo
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:

Naiyer Rizvi, MD

nar2144@cumc.columbia.edu

646-317-3141

YesYes2